Additional file 1 of Estimates and trends of the global burden of NASH-related liver cancer attributable to high fasting plasma glucose in 1990–2019: analysis of data from the 2019 Global Burden of Disease Study

Additional file 1:Table S1. Deaths of NASH-related liver cancer attributable to HFPG in 1990 and 2019, and its temporal trends from 1990 to 2019. Table S2. YLDs of NASH-related liver cancer attributable to HFPG in 1990 and 2019, and its temporal trends from 1990 to 2019. Table S3. YLLs of NASH-related liver cancer attributable to HFPG in 1990 and 2019, and its temporal trends from 1990 to 2019. Table S4. Deaths and DALYs of NASH-related liver cancer attributable to HFPG in countries and territories. Table S5. EAPC of NASH-related liver cancer deaths and DALYs attributable to HPFG in countries and territories. Figure. S1. The deaths of NASH-related liver cancer attributable to HFPG in countries and territories. (A) The ASR of NASH-related liver cancer deaths attributable to HFPG in 2019; (B) The relative change in percentage of NASH-related liver cancer deaths attributable to HFPG between 1990 and 2016. ASR, age-standardized rate. Figure. S2. The DALYs of NASH-related liver cancer attribute to HFPG in countries and territories. (A) The ASR of DALYs of NASH-related liver cancer attributable to HFPG in 2019; (B) The relative change in percentage of NASH-related liver cancer DALYs attributable to HFPG between 1990 and 2016. ASR, age-standardized rate. DALYs, disability adjusted life years. Figure. S3. The clusters of countries and territories in terms of the temporal trends of the NASH-related liver cancer burden attributable to HFPG. Figure. S4: Temporal trend of deaths rate of NASH-related liver cancer attributable to HFPG for different age group, 1990–2019.